EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeted therapies in retinoblastoma: GD2-directed immunotherapy following autologous stem cell transplantation and evaluation of alternative target B7-H3

Thomas Eichholz, Florian Heubach, Anne-Marie Arendt, Christian Seitz, Ines B Brecht, Martin Ebinger, Tim Flaadt, Daniela Süsskind, Lisa Richter, Isabel Hülsenbeck, Leonie Zerweck, Sophia Göricke und 7 weitere

Cancer Immunology, Immunotherapy · 2024-01 · 73 (1)

DOI: 10.1007/s00262-023-03587-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 19.01.2024. Verfasst von Thomas Eichholz und 18 weiteren Autor:innen. Beteiligte Einrichtung: University Children's Hospital, Eberhard Karls University, Abteilung I, Hoppe-Seyler-Str. 1, 72076, Tuebingen, Germany. Thomas.eichholz@med.uni-tuebi…. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Retinoblastoma, Retinal Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: excellence cluster iFIT (EXC 2180) [Gefördert durch die Deutsche Forschungsgemeinschaft (DFG) im Rahmen der Exzellenzstrategie des Bundes und der Länder], German Cancer Consortium, Dieter Schwarz Stiftung Neckarsulm.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

GD2-directed immunotherapy is highly effective in the treatment of high-risk neuroblastoma (NB), and might be an interesting target also in other high-risk tumors.

Methods

The German-Austrian Retinoblastoma Registry, Essen, was searched for patients, who were treated with anti-GD2 monoclonal antibody (mAb) dinutuximab beta (Db) in order to evaluate toxicity, response and outcome in these patients. Additionally, we evaluated anti-GD2 antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) in retinoblastoma cell lines in vitro. Furthermore, in vitro cytotoxicity assays directed against B7-H3 (CD276), a new identified potential target in RB, were performed.

Results

We identified four patients with relapsed stage IV retinoblastoma, who were treated with Db following autologous stem cell transplantation (ASCT). Two out of two evaluable patients with detectable tumors responded to immunotherapy. One of these and another patient who received immunotherapy without residual disease relapsed 10 and 12 months after start of Db. The other patients remained in remission until last follow-up 26 and 45 months, respectively. In vitro , significant lysis of RB cell lines by ADCC and CDC with samples from patients and healthy donors and anti-GD2 and anti-CD276-mAbs were demonstrated.

Conclusion

Anti-GD2-directed immunotherapy represents an additional therapeutic option in high-risk metastasized RB. Moreover, CD276 is another target of interest.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationRetinoblastomaRetinal NeoplasmsHumansTransplantation, AutologousNeoplasm Recurrence, LocalImmunotherapyGangliosidesB7 Antigens

Stichwörter der Autor:innen

B7-H3CD276Dinutuximab betaGD2RetinoblastomaTargeted therapy

Substanzen

GangliosidesCD276 protein, humanB7 Antigens

Autor:innen und Institutionen

  • University Children's Hospital, Eberhard Karls University, Abteilung I, Hoppe-Seyler-Str. 1, 72076, Tuebingen, Germany. Thomas.eichholz@med.uni-tuebingen.de.
  • University Children's Hospital, Eberhard Karls University, Abteilung I, Hoppe-Seyler-Str. 1, 72076, Tuebingen, Germany.
  • Department of Ophthalmology, Eberhard Karls University, Tuebingen, Germany.
  • Department of Pediatrics III, University Children's Hospital Essen, University of Duisburg-Essen, Essen, Germany.
  • Department of Ophthalmology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
  • Department of Radiology, Diagnostic and Interventional Neuroradiology, Eberhard Karls University, Tuebingen, Germany.

Förderung

  • excellence cluster iFIT (EXC 2180) [Gefördert durch die Deutsche Forschungsgemeinschaft (DFG) im Rahmen der Exzellenzstrategie des Bundes und der Länder]
  • German Cancer Consortium
  • Dieter Schwarz Stiftung Neckarsulm
  • Foerderverein and the Stiftung fuer krebskranke Kinder Tuebingen e.V.
  • Universitätsklinikum Tübingen

Zitieren

APA

Eichholz, T., Heubach, F., Arendt, A. M., Seitz, C., Brecht, I. B., Ebinger, M., Flaadt, T., Süsskind, D., Richter, L., Hülsenbeck, I., Zerweck, L., Göricke, S., Paulsen, F., Dombrowski, F., Flotho, C., Schönberger, S., Ketteler, P., Schulte, J., & Lang, P. (2024). Targeted therapies in retinoblastoma: GD2-directed immunotherapy following autologous stem cell transplantation and evaluation of alternative target B7-H3. Cancer Immunology, Immunotherapy, 73(1). https://doi.org/10.1007/s00262-023-03587-0

Vancouver

Eichholz T, Heubach F, Arendt AM, Seitz C, Brecht IB, Ebinger M, et al. Targeted therapies in retinoblastoma: GD2-directed immunotherapy following autologous stem cell transplantation and evaluation of alternative target B7-H3. Cancer Immunology, Immunotherapy. 2024;73(1). doi:10.1007/s00262-023-03587-0

BibTeX
@article{Eichholz2024,
  author = {Eichholz, Thomas and Heubach, Florian and Arendt, Anne-Marie and Seitz, Christian and Brecht, Ines B and Ebinger, Martin and Flaadt, Tim and Süsskind, Daniela and Richter, Lisa and Hülsenbeck, Isabel and Zerweck, Leonie and Göricke, Sophia and Paulsen, Frank and Dombrowski, Frank and Flotho, Christian and Schönberger, Stefan and Ketteler, Petra and Schulte, Johannes and Lang, Peter},
  title = {Targeted therapies in retinoblastoma: GD2-directed immunotherapy following autologous stem cell transplantation and evaluation of alternative target B7-H3},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2024},
  volume = {73},
  number = {1},
  doi = {10.1007/s00262-023-03587-0}
}
Kostenlos starten →